Protein Binding Assays Market (2026 - 2033)

Protein Binding Assays Market Summary

The global protein binding assays market size was valued at USD 550.5 million in 2025 and is projected to grow from USD 605.3 million in 2026 to USD 1,199.8 million in 2033, at a CAGR of 10.3% from 2026 to 2033. North America dominated the market, accounting for a largest revenue share of 40.0% in 2025. Protein binding assays from biochemistry and molecular biology are assessment methods to study the molecular behavior between proteins, nucleic acids, or a combination of proteins and nucleic acids.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The use of advanced technologies for preclinical assessments and funding for novel drug discovery contribute to the capabilities of these assessments.

The increase in protein binding tests is becoming necessary due to the prevalence of chronic diseases. This drives the need for medications to treat patients better. Other factors, such as growth in research and development spending and the launch of novel, high-efficacy drugs, are encouraging market growth. Besides, the rise in research and development has resulted in easier, faster assay methods through greater use.

Protein binding assays enhance the targeted therapies and minimize the quantity of target molecules. The growing demand for protein binding assays in the past few years, owing to the significance of proteins for biological processes, is driving the market growth. In addition, protein binding tests produce personalized medicine and medical therapy based on individual characteristics. Technological advancements have enabled the development of high-accuracy, high-sensitivity assays that can be incorporated into analytical tools. Protein binding assay methods have become more precise, effective, and efficient over the past several years. The partnerships and collaborations among the pharmaceutical industry, institutions, and contract research organizations have led to the emergence of cutting-edge technologies that facilitate drug discovery and development.

Analyst Perspective

The global protein binding assays market continues to grow steadily, supported by increased investment in drug discovery, biologics development, and precision medicine research. Equilibrium dialysis remains the leading technology, valued for its accuracy and broad adoption in protein binding studies. The outsourcing of research to CROs and ongoing improvements in biomolecular interaction analysis are further driving market expansion. Companies that develop high-throughput, sensitive assay platforms and broaden their service offerings are well positioned to enhance their competitiveness in this evolving market.

Technology insights

Equilibrium dialysis dominated the protein binding assays industry with a share of around 50.0% in 2025. Scientists and researchers prefer this technique for its low cost and high accuracy. In addition, the increased focus on the discovery of new drugs and development in the pharmaceutical and biotechnological industries further fuels the market growth.

The surface plasmon resonance (SPR) market segment is expected to grow at the fastest CAGR during the forecast period. Factors such as the increase in the adoption of technology in drug discovery and development processes and the real-time monitoring of biomolecular interactions are responsible for its popularity. In addition, the growing demand for high-throughput screening methods, advanced analytical techniques, and cost-effective drug discovery propels segment growth.

Product & Service Insights

The services segment dominated the protein-binding assay market, accounting for around 45.0% share in 2025. Technological advancements, strategic investments, and increasing consumer demand constitute market growth. In addition, the major companies in the sector are focusing on innovation to meet a wide range of needs for their customers. The incorporation of advanced technology, such as the Internet of Things and artificial intelligence, has significantly impacted efficiency and functionality. For instance, in October 2025, Charles River Laboratories and X-Chem formed a strategic collaboration to integrate protein production, downstream assay development, and DNA-encoded library screening for hit identification. This partnership broadens their services in early-stage drug discovery and protein-binding research. The launch of new products with enhanced capabilities is expected to drive market growth.

The kits and reagents segment is expected to grow at a rapid CAGR over the forecast period. Factors such as ready-to-use customization and the ability to measure protein biomarkers used in drug discovery and disease diagnostics contribute to the segment’s growth. Furthermore, the increasing number of repeat purchases from laboratories is also significant to the demand.

End Use Insights

The pharmaceuticals and biotechnology segment dominated the protein binding assays market with over 45.0% share in 2025. Factors such as a wide and strong distribution network and significant investments in drug discovery boost the segment growth. Pharmaceuticals cater to the end user’s needs, and medications are offered based on the disease profile, as prescribed by a medical professional.

The Contract Research Organization (CRO) segment is expected to grow at the fastest CAGR during the forecast period. Factors such as expertise in assisting biologics developers in navigating complex processes and regulations across various geographies drive their significance. Besides, CRO support for biopharmaceutical assessment methods is crucial. In addition, major organizations are increasingly outsourcing research tasks and activities to third parties to optimize their workload. This further enhances the research quality.

Regional Insights

The North America protein binding assays market held the largest global share of approximately 40.0% in 2025. The rising prevalence of chronic diseases in the population and government initiatives in countries such as the U.S., Canada, and Mexico contribute to their success. Increasing clinical trials, the rising number of biosimilars and biologics, and the demand for efficient and effective biologics are responsible for the dominance and growth of the market. In addition, in October 2025, Promega Corporation and MilliporeSigma partnered to integrate their assay and cell biology technologies. This collaboration aims to develop advanced workflows for protein interaction studies and accelerate drug discovery, supporting continued innovation in protein binding research.

To learn more about this report, Download Free Sample Report

U.S. Protein Binding Assays Market Trends

The U.S. protein binding assays industry dominated North America with a share of over 75.0% in 2025. Factors such as favorable policies, an emphasis on developing novel drugs, drug efficacy, and the participation of CROs and biopharmaceutical companies encourage market growth. In addition, the growing initiatives by the government in support of biologics development, and the presence of major pharmaceutical players with innovative strategies, further boost the market developments.

Europe Protein Binding Assays Market Trends

Europe protein binding assays industry is expected to witness significant growth in the coming years, owing to factors such as the development of pharmacological assays and the discovery of a wide range of drug molecules and receptors, which are the key factors for the market growth. With the increasing adoption of protein-based drugs and the availability of advanced technologies for protein binding, the heavy investments by major players are further boosting the market.

The UK protein binding assays market growth is highly anticipated over the forecast period as government initiatives and technological bases for drug discovery and development catalyze the clinical industry. Besides, the presence of advanced medical technology and heavy investment by the biologics organizations in protein binding has shaped the regional market.

Asia Pacific Protein Binding Assays Market Trends

The Asia Pacific protein binding assays industry is expected to grow at the fastest CAGR over the forecast period. This growth is driven by the increasing number of CRO operations, rising drug discovery and healthcare expenditures in countries such as China, India, and Japan. In addition, the rise in research activities by the major players and the growing interest in molecular technology supplement the regional market developments.

Key Protein Binding Assays Companies Insights

Some major players in the protein binding assays market include Thermo Fisher Scientific Inc.; ADMEcell, Inc.; and Sartorius AG. Organizations focus on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are undertaking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies.

Key Protein Binding Assays Companies

The following key companies have been profiled for this study of the protein binding assays market.

• Thermo Fisher Scientific Inc.

• ADMEcell, Inc.

• Beckman Coulter, Inc.

• Sartorius AG

• Bio-Rad Laboratories, Inc.

• Abzena Ltd

• Abcam Limited

• GVK Biosciences Private Limited

• Promega Corporation

• Arrayit Corporation

• Charles River Laboratories

• Sovicell

• Eurofins Scientific

• 3B Pharmaceuticals GmbH

• Creative Biolabs

• Evotec SE

• BioDuro

• Merck KGaA

Recent Developments

• In May 2025, Sartorius AG launched the Octet R8e System, a next-generation biolayer interferometry platform for real-time, high-throughput analysis of protein-protein, label-free, and other biomolecular interactions. The system features improved sensitivity, compatibility with 384-well plates, and longer assay run times to advance drug discovery and protein binding research.
• In May 2024, Beckman Coulter received a clearance from the U.S. Food and Drug Administration for its Access NT-proBNP assay using the Beckman Coulter Dxl 9000 Immunoassay Analyzer that assesses heart failure in less than 11 minutes.

Global Protein Binding Assays Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global protein binding assays market report based on technology, product & service, end use, and region:

• Technology Outlook (Revenue, USD Billion, 2021 - 2033

  • Instruments

  • Kits & Reagents

  • Services

• Product & Service Outlook (Revenue, USD Billion, 2021 - 2033)

  • Ultracentrifugation

  • Equilibrium Dialysis

  • Ultrafiltration

  • Surface Plasmon Resonance

  • Others

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Contract Research Organizations

  • Pharmaceutical & Biotechnology Companies

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Denmark

    • Norway

    • Sweden

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • UAE

    • Kuwait

    • South Africa